Organization
Henan Cancer Hospital, Zhengzhou, China
7 abstracts
Abstract
Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.Org: Institute of Hematology and Blood Disease Hospital, CAMS & PUMC, Tianjin, China, Henan Cancer Hospital, Zhengzhou, China, The Second Hospital of HeBei Medical University, Shijiazhuang, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Institute of Hematology and Oncology, Harbin the First Hospital, Harbin, China,
Abstract
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Second Department of Thoracic Tumors, Peking University Cancer Hospital, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology,
Abstract
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.Org: Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Linyi Cancer Hospital, Linyi, China, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China,
Abstract
First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.Org: Sarah Cannon Research Institute at HealthONE, Denver, CO, Jiangsu Province Hospital, Nanjing, China, Winship Cancer Institute, Atlanta, GA, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Henan Cancer Hospital, Zhengzhou, China,
Abstract
TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).Org: Department of oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Department of Breast Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Department of Breast Medicine, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China,
Abstract
SI-B003 (PD-1/CTLA-4) in patients with advanced solid tumors: A phase I study.Org: Department of Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, China, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China, Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Henan Cancer Hospital, Zhengzhou, China, Shanghai General Hospital, Shanghai, China,
Abstract
Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The central hospital of lishui city, Lishui, China, Department of Gastroenterology,Harbin Medical University Cancer Hospital, Harbin, China, Hunan Provincial People's Hospital, Changsha, China,